6 research outputs found
Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients
We have previously identified UMP-CMP kinase (CMPK1) as a prognostic marker for triple negative breast cancer (TNBC) by mass spectrometry (MS). In this study we evaluated CMPK1 association to prognosis in an independent set of samples by immunohistochemistry (IHC) and assessed biological pathways associated to its expression through gene set enrichment analysis (GSEA). A total of 461 TNBC paraffin-embedded tissues were collected from different academic hospitals in Europe, incorporated into tissue micro-arrays (TMA), and stained for CMPK1 expression. We also collected gene expression data of 60 samples, which were also present in the TMA, for GSEA correlation analysis. CMPK1 IHC staining showed both cytoplasmic and nuclear components. While cytoplasmic CMPK1 did not show any association to metastasis free survival (MFS), nuclear CMPK1 was associated to poor prognosis independently from other prognostic factors in stratified Cox regression analyses. GSEA correlation analysis of the nuclear CMPK1-stratified gene expression dataset showed a significant enrichment of extracellular matrix (ECM; positive correlation) and cell cycle (negative correlation) associated genes. We have shown here that nuclear CMPK1 is indicative of poor prognosis in TNBCs and that its expression may be related to dysregulation of ECM and cell cycle molecules
The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome
CD146, involved in epithelial-to-mesenchymal transition (EMT), might affect cancer
aggressiveness. We here investigated the prevalence of CD146 expression in breast cancer subtypes,
its relation to prognosis, the relation between CD146 and EMT and the outcome to tamoxifen.
Primary breast cancer tissues from 1342 patients were available for this retrospective study and
immunohistochemically stained for CD146. For survival analyses, pure prognosis was studied by
only including lymph-node negative patients who did not receive (neo)adjuvant systemic treatment
(n = 551). 11% of the tumors showed CD146 expression. CD146 expression was most prevalent in
triple-negative cases (64%, p < 0.001). In univariable analysis, CD146 expression was a prognostic
factor for both metastasis-free survival (MFS) (p = 0.020) and overall survival (OS) (p = 0.037), but not
in multivariable analysis (including age, tumor size, grade, estrogen receptor (ER), progesterone
receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67). No correlation between
CD146 and EMT nor difference in outcome to first-line tamoxifen was seen. In this large series,
our data showed that CD146 is present in primary breast cancer and is a pure prognostic factor for
MFS and OS in breast cancer patients. We did not see an association between CD146 expression and
EMT nor on outcome to tamoxifen
Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer
New therapies are an urgent medical need in all breast cancer subgroups. Metabotropic glutamate receptor 1 (mGluR1) is suggested as a potential new molecular target. We
Loss of Y-Chromosome during Male Breast Carcinogenesis
Loss of Y-chromosome (LOY) is associated with increased cancer mortality in males.
The prevalence of LOY in male breast cancer (BC) is unknown. The aim of this study is to assess the
presence and prognostic effect of LOY during male BC progression. We included male BC patients
diagnosed between 1989 and 2009 (n = 796). A tissue microarray (TMA) was constructed to perform
immunohistochemistry and fluorescent in situ hybridization (FISH), using an X and Y probe. We
also performed this FISH on a selected number of patients using whole tissue slides to study LOY
during progression from ductal carcinoma in situ (DCIS) to invasive BC. In total, LOY was present in
12.7% (n = 92) of cases, whereby LOY was associated with ER and PR negative tumors (p = 0.017 and
p = 0.01). LOY was not associated with the outcome. Using whole slides including invasive BC and
adjacent DCIS (n = 22), we detected a concordant LOY status between both components in 17 patients.
In conclusion, LOY is an early event in male breast carcinogenesis, which generally starts at the DCIS
stage and is associated with ER and PR negative tumor
The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer
Background: In breast cancer (BC), recurrent fusion genes of estrogen receptor alpha (ESR1) and AKAP12, ARMT1 and CCDC170 have been reported. In these gene fusions the ligand binding domain of ESR1 has been replaced by the transactivation domain of the fusion partner constitutively activating the receptor. As a result, these gene fusions can drive tumor growth hormone independently as been shown in preclinical models, but the clinical value of these fusions have not been reported. Here, we studied the prognostic and predictive value of different frequently reported ESR1 fusion transcripts in primary BC. Methods: We evaluated 732 patients with primary BC (131 ESR1-negative and 601 ESR1-positive cases), including two ER-positive BC patient cohorts: one cohort of 322 patients with advanced disease who received first-line endocrine therapy (ET) (predictive cohort), and a second cohort of 279 patients with lymph node negative disease (LNN) who received no adjuvant systemic treatment (prognostic cohort). Fusion gene transcript levels were measured by reverse transcriptase quantitative PCR. The presence of the different fusion transcripts was associated, in uni- and multivariable Cox regression analysis taking along current clinico-pathological characteristics, to progression free survival (PFS) during first-line endocrine therapy in the predictive cohort, and disease- free survival (DFS) and overall survival (OS) in the prognostic cohort. Results: The ESR1-CCDC170 fusion transcript was present in 27.6% of the ESR1-positive BC subjects and in 2.3% of the ESR1-negative cases. In the predictive cohort, none of the fusion transcripts were associated with response to first-line ET. In the prognostic cohort, the median DFS and OS were respectively 37 and 93 months for patients with an ESR1-CCDC170 exon 8 gene fusion transcript and respectively 91 and 212 months for patients without this fusion transcript. In a multivariable analysis, this ESR1-CCDC170 fusion transcript was an independent prognostic factor for DFS (HR) (95% confidence interval (CI): 1.8 (1.2–2.8), P = 0.005) and OS (HR (95% CI: 1.7 (1.1–2.7), P = 0.023). Conclusions: Our study shows that in primary BC only ESR1-CCDC170 exon 8 gene fusion transcript carries prognostic value. None of the ESR1 fusion transcripts, which are considered to have constitutive ER activity, was predictive for outcome in BC with advanced disease treated with endocrine treatment
Ferritin heavy chain in triple negative breast cancer: A favorable prognostic marker that relates to a cluster of differentiation 8 positive (CD8+) effector t-cell response
Ferritin heavy chain (FTH1) is a 21-kDa subunit of the ferritin complex, known for its role in iron metabolism, and which has recently been identified as a favorable prognostic protein for triple negative breast cancer (TNBC) patients. Currently, it is not well understood how FTH1 contributes to an anti-tumor response. Here, we explored whether expression and cellular compartmentalization of FTH1 correlates to an effective immune response in TNBC patients. Analysis of the tumor tissue transcriptome, complemented with in silico pathway analysis, revealed that FTH1 was an integral part of an immunomodulatory network of cytokine signaling, adaptive immunity, and cell death. These findings were confirmed using mass spectrometry (MS)-derived proteomic data, and immunohistochemical staining of tissue microarrays. We observed that FTH1 is localized in both the cytoplasm and/or nucleus of cancer cells. However, high cytoplasmic (c) FTH1 was associated with favorable prognosis (Log-rank p = 0.001), whereas nuclear (n) FTH1 staining was associated with adverse prognosis (Log-rank p = 0.019). cFTH1 staining significantly correlated with total FTH1 expression in TNBC tissue samples, as measure